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Abstract 
Amyotrophic lateral sclerosis (ALS) is characterised by motor neurone loss resulting in 
muscle weakness, spasticity and ultimately death.  Whilst most cases are sporadic, 5-10% 
are caused by inherited mutations, most commonly C9ORF72, SOD1, TARDBP and FUS.  
Rarer genetic causes of ALS include mutation of optineurin (OPTN).  Furthermore, the 
optineurin protein has been localised to the ubiquitylated protein aggregates in several 
neurodegenerative diseases, including ALS.   
This study 1) used sequencing to investigate the frequency of OPTN mutations in ALS 
patients from the North of England, 2) characterised the clinical and neuropathological 
features of ALS associated with a mutation of OPTN, 3) investigated optineurin 
neuropathology in C9ORF72-related ALS (C9ORF72-ALS). 
Screening of 42 familial and 47 sporadic ALS cases identified a heterozygous p.E322K 
missense mutation in exon 10 of OPTN in one familial ALS patient who additionally had a 
mutation of C9ORF72.  This patient had bulbar, limb and respiratory symptoms and signs 
without obvious cognitive problems.  Neuropathological examination revealed motor neurone 
loss, TDP-43-positive neuronal and glial cytoplasmic inclusions together with the TDP-43-
negative neuronal cytoplasmic inclusions in extra motor regions that are characteristic of 
C9ORF72-ALS.  We have demonstrated the novel neuropathological finding that both TDP-
43-positive and negative inclusion types had positive staining for optineurin by 
immunohistochemistry.  We went on to show that optineurin was present in TDP-43-negative 
cytoplasmic extra motor inclusions in C9ORF72-ALS cases that do not carry OPTN 
mutations.   
We conclude that: 1) OPTN mutations appear to be associated with ALS; 2) Optineurin 
protein is present in a subset of the extramotor inclusions of C9ORF72-ALS; 3) It is not 
uncommon for multiple ALS-causing mutations to occur in the same patient and 4) Studies 
of optineurin are likely to provide useful data regarding the pathophysiology of ALS in 
particular and neurodegenerative disease in general.   
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Introduction 
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neurone disease 
(MND).  It is characterised by relentless degeneration of vulnerable neuronal cell 
populations, principally upper and lower motor neurones of the precentral gyrus, brainstem 
and spinal cord.  This results in muscle weakness, atrophy and spasticity, leading to 
widespread paralysis that culminates in respiratory failure, typically within 2 to 3 years from 
the point of diagnosis1.  ALS has an incidence of approximately 2 individuals per 100,0002 
with a slight male preponderance3.  Pathologically, classical ALS is characterised by motor 
neurone loss with ubiquitylated neuronal cytoplasmic inclusions of TDP-434.   
 
Approximately 5-10% of ALS cases are classified as familial (fALS), where ALS is 
documented in a first or second degree relative, whereas the remainder are deemed 
sporadic (sALS), appearing to occur without a relevant family history5.  The first ALS gene 
found to cause fALS was SOD1 in 19936 and since the discovery that TARDBP mutations 
can cause ALS in 20067, the number of known of ALS-causing genes has grown rapidly to 
over 20 (alsod.iop.kcl.ac.uk). We now know the genetic aetiology of approximately two thirds 
of familial cases and 11% of sporadic cases8, following the identification of the GGGGCC 
repeat expansion in the C9ORF72 gene in 40-50% of fALS cases9, 10. 
 
Several mutations have been identified within the optineurin (OPTN) gene on chromosome 
10 that are reported to cause ALS, first in Japanese, then in European and Scandinavian 
populations11-16.  However, a number of studies have failed to find OPTN mutations in ALS 
patients17-20, suggesting this to be a rare occurrence. 
 
OPTN mutations have long been known to cause the neurodegenerative disorder primary 
open angle glaucoma (POAG)21, and, more recently have been associated with Paget’s 
disease of bone22.  The OPTN gene spans 37kb on chromosome 10, has 3 non-coding 
exons and 13 exons that encode a 577 amino acid, 67kDa protein which functions as a 
dimer23.  It shares a 53% similarity with the NFB essential modulator (NEMO) at both the 
primary sequence and domain organisation levels24.  It has two coiled-coils, a ubiquitin 
binding domain, a ubiquitin-binding zinc finger, a microtubule associated protein 1 light chain 
3 (LC3)-interacting motif and a zinc finger25. It is a ubiquitously expressed cytosolic protein 
that primarily localises to the perinuclear region of the cell where it associates with the Golgi 
apparatus and is known to interact with a plethora of molecules including the type 1a 
metabotropic glutamate receptor and huntingtin26, 27.  It is involved in multiple cellular 
functions and signalling pathways, including down regulation of the NFB pathway, 
protection against oxidative stress-induced apoptosis, membrane trafficking and Golgi 
organisation, protein secretion and regulation of mitotic progression23.   
 
The aim of this study was to establish the contribution of OPTN mutations as a genetic 
cause of fALS and sALS in a Caucasian cohort from the North of England.  On finding a 
case with simultaneous OPTN and C9ORF72 mutations, we proceeded to characterise the 
neuropathology, and elucidated the degree of optineurin incorporation into the TDP-43-
negative ubiquitylated neuronal cytoplasmic inclusions of C9ORF72-ALS.  
 
Materials and Methods 
Genetic screening 
Our cohort consisted of 42 familial (35 classical ALS, 3 PMA, 1 PLS, 1 PBP, 1 ALS+FTD 
and 1 ALS+PD) and 47 sporadic (39 classical ALS, 1 PMA, 1 PBP, 5 ALS+FTD and 1 
ALS+MSA) cases in the Sheffield MND Blood DNA and Brain Tissue Banks.  Control 
samples (n=375) were recruited from neurologically normal, age and gender matched 
healthy volunteers.  Informed written consent was obtained from all participants prior to the 
collection of blood or from their immediate families prior to autopsy.  The study was 
approved by the South Sheffield Research Ethics Committee.            
Patients (n=89), 48 male and 41 female (M:F ratio 1.17:1), were diagnosed between June 
1990 and December 2008 with suspected, probable or definite ALS according to the 1998 
revised El Escorial Rating criteria defined by the World Federation of Neurology.  Age at 
symptom onset ranged from 27 to 88 years with a respective mean disease duration of 28 
and 41 months for familial and sporadic cases respectively.  Onset occurred focally in at 
least 90% of patients.  Of these, approximately two thirds presented with asymmetric upper 
or lower limb dysfunction, one third presented with bulbar symptoms and <2% exhibited 
clinical evidence of cognitive impairment.     
Genomic material isolated from whole venous blood (n=34) or snap frozen cerebral cortex 
(n=55) was extracted using the Nucleon® BACC3 (Tepnel Life Sciences PLC, UK) and Soft 
Tissue (GE Healthcare Ltd, UK) kits according to the manufacturers guidelines.  
Subjects had previously been screened for mutations in TARDBP28, SOD129, FUS30 and 
were subsequently screened for C9ORF7231. 
The promoter region, 3 non-coding exons, 13 coding exons, intron/exon boundaries and 
splice acceptor/donor sites of the OPTN gene (Ensembl transcript ID: ENST00000378748) 
were screened using previously published primer sequences (Eurofins MWG Operon, 
Germany)11.  PCR reactions were performed in a total volume of 20µl as described 
previously32.  Post optimization, an initial denaturation step of 950C for 5 min was followed by 
35 cycles of 950C (30 sec), 520C (30 sec) and 720C (45 sec) followed by a final extension of 
720C for 10 min for exons 5, 7, 9 and 13.  The remaining exons were amplified using an 
annealing temperature of 540C.  The size of the PCR products were verified by agarose gel 
electrophoresis prior to purification using Exonuclease (New England Biolabs, UK) and 
shrimp alkaline phosphatase (SAP) (USB Corporation, UK).  Sequencing was performed in 
house at the University of Sheffield Core Genomics Facility.  Samples were run on a 
BigDye® v3.1 Terminator machine and ABI 3730 capillary analyser (Applied Biosystems, 
UK).  Potential mutations or coding polymorphisms were confirmed by bi-directional 
sequencing in a second PCR reaction.  
Control subjects were screened for the non-synonymous c.293T>A (p.M98K) polymorphism 
in exon 5 by restriction enzyme digest using Stu1 (New England Biolabs, UK), whilst direct 
sequencing determined the frequency of the potential missense mutation in exon 10 
c.964G>A (p.E322K).  C9ORF72 screening and southern blotting methods have been 
described elsewhere31, 33.          
Neuropathology 
The brain and spinal cord from all cases assessed for neuropathology were donated to the 
Sheffield Brain Tissue Bank with the consent of the next of kin and with ethics committee 
approval.  The CNS tissue handling, dissection and histological preparation with OPTN 
immunohistochemistry performed using a rabbit polyclonal antibody (Abcam ab79110, 1:50 
dilution; antigen retrieval at pH9) were performed using standard protocols for our 
laboratory31.  
Optineurin immunohistochemistry was also performed on the spinal cord from the proband, 1 
neurologically healthy control, 3 cases of sporadic ALS, 1 case of FUS-ALS (p.R524W, 
previously reported as case 130), 1 case of SOD1-ALS (p.I114T), 6 cases of C9ORF72-ALS 
and the hippocampus from 12 cases of C9ORF72-ALS.  Immunohistochemistry for ubiquitin 
(antigen retrieval at pH9 in A. Menarini Access Super RTU in pressure cooker; Dako Z0458 
primary antibody used at 1:400 dilution) and optineurin was performed on adjacent sections 
of spinal cord from the proband. Immunohistochemistry for p62, TDP-43 and poly-GA 
dipeptide repeat was performed as described elsewhere31, 34.  We are grateful to Prof Dieter 
Edbauer of the German Centre for Neurodegenerative Diseases, Munich for the kind gift of 
the poly-GA antibody.   
Adjacent sections of spinal cord from    
Results 
Mutation Screening 
Screening analysis of the 16 exons of OPTN, including intron/exon boundaries, in 42 fALS 
and 47 sALS index cases identified two non-synonymous substitutions in exons 5 and 10 
and one novel intronic substitution.  In addition, sequencing also identified seventeen 
previously identified single nucleotide polymorphisms (SNPs) including two upstream of the 
coding region, eleven intronic variants as well as two 5’UTR and two synonymous 
substitutions (Table 1). 
A heterozygous c.964G>A (p.E322K) missense mutation (rs523747) was identified in exon 
10 of one fALS individual (Figure 1a; the proband), which was absent from 375 unrelated 
neurologically normal control subjects (Figure 1b).  The negatively charged glutamic acid, 
which is substituted to a positively charged lysine in the coiled coil II domain, is highly 
conserved across a diverse range of species, including mammals, chicken, zebrafish and 
treefrog (Figure 2).  The p.E322K mutation is described as a missense variant by Ensembl 
and is predicted to be pathogenic according to Polyphen (probably damaging) and SIFT 
(deleterious; Ensembl predicted consequences; Table 2).  Our screening of 375 controls 
failed to detect any carriers, and the worldwide minor allele frequency reported by the 1000 
Genomes Project Phase 3 is 0.01, having sequenced 2504 individuals. The mutation is listed 
as having an allele frequency of 0.001 in the European population (having screened 502 
Europeans in the 1000 Genomes Phase 3), due to a single individual having being identified 
in the UK out of 90 individuals screened.  Whilst it is reported to be found more frequently in 
the African population (0.023%), it is absent from East and Southern Asian populations and 
only seen in 2 individuals of 692 individuals screened from the Americas 
(Colombia/Mexico/Puerto Rica origin) (1000 Genomes Project Phase 3). We therefore 
believe this variant to be a mutation.  
Interestingly, the proband was subsequently found to carry a hexanucleotide repeat 
expansion in C9ORF72.  Southern blotting on DNA extracted from venous blood, cerebellum 
and frontal cortex revealed somatic heterogeneity, but in all tissues repeat length was >600 
units. 
The heterozygous non-synonymous c.293T>A (p.M98K) change in exon 5 (rs11258194) 
was detected in six fALS cases and one sALS patient.  The methionine to lysine substitution 
occurs within the binding site of Rab8 and is situated in the coiled coil I domain of optineurin.  
This nucleotide change was also found in 4.15% of controls screened, a frequency similar to 
that of 4.5% seen in the 1000 Genomes Phase 1 data for Europe. Consistent with the 
presence of the allele within the normal population, in silico analysis using PolyPhen and 
SIFT suggests the alteration is non-pathogenic.  
The novel intronic polymorphism was not predicted to alter any splice sites according to 
Flybase analysis.  Of the other SNPs identified, the frequencies of these within our ALS 
cohort were comparable to those reported within the 1000 Genomes Project Phase1. 
Clinical Phenotype 
The proband (II:5) was a Caucasian female who in her past had suffered with migraine, a 
ruptured ovarian cyst and had undergone a hysterectomy for menorrhagia.  Of note she had 
a significant family history of ALS.  Her father (I:4) was diagnosed with bulbar onset ALS and 
dementia and died aged 74 years.  Additionally a male paternal cousin (II:3) also developed 
MND and died aged 34 years (DNA was not available from this individual for analysis).  The 
proband presented with a 6 month history of dysphagia and dysarthria.  She subsequently 
progressed to develop limb weakness 7 months into the illness, resulting in falls and 
significant hand weakness, which impaired her ability to perform activities of daily living.  She 
also reported troublesome emotional lability.    
On examination she exhibited mixed upper and lower motor signs in the bulbar and limb 
regions.  The tongue was wasted with prominent fasciculations.  There was significant 
weakness of her arm muscles, in particular of abductor pollicus brevis bilaterally.  Tone was 
increased in the legs and all of the tendon reflexes were brisk.  The limb weakness and 
bulbar symptoms deteriorated with rapid progression.  The patient did not have glaucoma.   
Investigations included magnetic resonance imaging (MRI) of the brain and cervical spine 
which was unremarkable.  Electromyography demonstrated widespread neurogenic changes 
fulfilling the El Escorial electrodiagnostic criteria for ALS.   
During the disease course, weakness progressed to the point the patient required hoisting 
for transfers.  A gastrostomy was performed 23 months into the illness due to severe 
dysphagia and malnutrition.  Respiratory function was relatively maintained.  However, she 
died following a cardiorespiratory arrest, approximately 30 months after symptom onset.   
Neuropathology 
Macroscopically the brain and spinal cord were unremarkable externally and on slicing.  
Microscopy revealed classical ALS neuropathology (Figure 3):  For the motor system, the 
spinal cord and medulla showed depleted numbers of lower motor neurones, whilst the 
motor cortex showed mild (predominantly layer II) vacuolation with negligible neuronal loss. 
Immunohistochemistry revealed glial and neuronal (both skein-like and compact) 
ubiquitylated cytoplasmic inclusions in residual motor neurones that were identified on p62 
and TDP-43 immunohistochemistry.  Long, pyramidal tract degeneration was highlighted by 
pallor of myelin staining in the lateral tracts of the spinal cord.  Immunohistochemistry for 
FUS showed normal, predominantly nuclear staining.   
Superimposed on this classical ALS neuropathology, was the extra-motor pathology that is 
the hallmark of C9ORF72-ALS.  Thus, in the hippocampus, there were multiple ubiquitylated 
(p62-positive, TDP-43-negative; henceforth TDP-43-negative inclusions).  These were also 
seen in the frontal neocortex and cerebellum, in common with other C9ORF72-ALS cases 
from our collection35.   
Immunohistochemistry for optineurin in neurologically healthy control tissue revealed 
expression in neuronal cytoplasm (including dendritic processes) and neuropil with a small 
amount of glial (predominantly astrocytic) expression (figure 4a).  Spinal cord from sporadic 
ALS cases revealed a similar pattern of staining (figure 4b), with the additional labelling of 
neuronal cytoplasmic inclusions (both compact and skein-like) as described by previous 
authors11, 36.   
Optineurin immunopositivity in neuronal cytoplasmic inclusions in the spinal cord anterior 
horn was also present in the index case (figure 4c).  Immunohistochemistry for ubiquitin or 
optineurin on adjacent sections revealed neurones that either had cytoplasmic inclusions 
positive for both optineurin and ubiquitin; or had no inclusions on either preparation 
(supplementary figure 1).  Interestingly, there was also labelling of some of the TDP-43 
negative inclusions, most readily apparent in the CA3-4 subfield of the hippocampus.  These 
were much harder to discern in the cerebellum, but were present (figures 4e, f).  
Fluorescence immunohistochemistry with double staining for optineurin and poly-(Gly-Ala)-
(GA) dipeptide repeat protein was performed on the cerebellum.  For optineurin, the 
cytoplasmic inclusions had signal intensity far in excess of  background.  Approximately 5% 
of inclusions staining for poly-(Gly-Ala)-(GA) dipeptide repeat protein also had intense 
expression of optineurin (Figure 4g). 
Having demonstrated optineurin labelling of the TDP-43-negative inclusions in the index 
case with an OPTN mutation, we hypothesised that the protein would also be present in the 
TDP-43-negative inclusions seen in cases of C9ORF72-ALS without mutations of OPTN.  
This was investigated by performing immunohistochemistry on the hippocampus of 12 such 
cases.  Optineurin-positive neuronal cytoplasmic inclusions were seen in CA3-4 in 10 (83%) 
of these cases.  In general, the number of Optineurin-positive inclusions was much smaller 
than the number of p62-positive inclusions.  Co-localisation of poly-GA and optineurin was 
also demonstrated in these cases. There was no obvious relationship between the number 
of optineurin-positive inclusions and the age of onset, duration of disease, site of symptoms 
onset or presence/absence of cognitive symptoms in the C9ORF72-ALS cases.   
Optineurin immunohistochemistry also labelled neuronal cytoplasmic inclusions in the cases 
of ALS due to mutations of FUS and SOD1.  This was as has been described previously for 
FUS mutations37.  In contrast with the existing literature11, optineurin-positive inclusions were 
distinct from hyaline conglomerate inclusions, which were unlabelled.   
Discussion 
In this study, we have screened a cohort of cases of ALS from the North of England, and 
identified a p.E322K mutation in OPTN.  The amino acid substitution is predicted to be 
pathogenic and has been previously reported as a cause of primary open angle glaucoma 
(POAG)23.  The amino acid is highly conserved throughout the species and was not found in 
750 chromosomes screened in age-matched controls from the same geographical region; 
only one other variant has been identified within a screen of 1004 European chromosomes, 
establishing it as a very rare variant, which we proposed to be associated with ALS. The 
individual was subsequently shown to carry a hexanucleotide expansion of C9ORF72.  
Reports of oligogenic inheritance in ALS are increasingly being published; mutations in 
C9ORF72 and SOD1, FUS, TARDBP, VAPB and other rarer variants have been identified, 
as well as mutations in angiogenin (ANG) along with SOD1, FUS, TARDBP and VAPB 
mutations and other double rare variants38-41.  The presence of additional genetic variants 
has been demonstrated to be associated with an earlier age of onset, suggesting additive or 
synergistic effects, in disease pathogenesis40. 
The p.E322K mutation described here is rare in the UK and European population and high 
levels of conservation are observed in multiple different species.  However, despite this 
mutation having been associated with POAG, the pathogenicity of this OPTN mutation in 
relation to ALS needs to confirmed experimentally, particularly given that this patient was 
subsequently shown to carry a hexanucleotide repeat expansion of C9ORF72 9, 10, 31. 
The patient with mutations in both OPTN and C9ORF72 had fairly classical clinical features 
of ALS.  Neuropathology of this case revealed 1) classical features of ALS, including TDP-
43-positive neuronal cytoplasmic inclusions with 2) superimposed features C9ORF72-ALS, 
namely TDP-43-negative ubiquitylated neuronal and glial cytoplasmic inclusions in extra 
motor regions.  We then proceeded to demonstrate that some of both the TDP-43-positive 
and TDP-43-negative inclusions showed positive immunoreactivity for optineurin.  
Following this, optineurin immunolabelling was demonstrated in the extra motor, TDP-43-
negative, ubiquitylated neuronal cytoplasmic inclusions in the hippocampus of 10/12 
C9ORF72-ALS cases that did not have a mutation of OPTN.  Immunofluorescence 
experiments also demonstrated these optineurin-positive inclusions in the cerebellum and 
demonstrated colocalisation with transcribed non-ATG-dependent dipeptide repeat protein 
poly-GA.   
ALS-causing GGGGCC, hexanucleotide repeat mutations of C9ORF72 were first described 
in 20119, 10 and account for the largest burden of both sporadic (~7%) and familial (~40%) 
ALS42.  Pathologically, this subtype of ALS is characterised by classical TDP-43-positive 
neuronal and glial cytoplasmic inclusions in the motor system.  Superimposed on this 
pathology are ubiquitylated cytoplasmic inclusions in extra motor regions that are TDP-43-
negative31, 43.  The absence of TDP-43 raised the question as to what the protein 
constituents of these inclusions were.  Subsequent studies have revealed these to contain 
dipeptide repeat proteins that have been translated from sense and antisense RNA 
transcripts in a non-ATG dependent manner44, 45.  Here we demonstrate the novel finding 
that many of these inclusions also contain optineurin.   
Optineurin has also been detected in proteinaceous inclusions in contexts outside of ALS 
including other neurodegenerative diseases such as neurofibrillary tangles and dystrophic 
neurites of Alzheimer’s disease, Lewy bodies of Parkinson’s disease, glial cytoplasmic 
inclusions of multiple system atrophy, Pick bodies in Pick disease, nuclear inclusions of 
polyglutamine diseases and Marinesco bodies46-48.  Thus, suggests that optineurin appears 
to be involved, at some level, in the general aetiology of many neurodegenerative 
proteinopathies.  That mutations of OPTN can cause neurodegenerative disease suggests 
that its role may be fundamental.   
Our findings demonstrate similarities between OPTN, ubiquilin 2 (UBQN2)49 and 
sequestosome 1 (SQSTM1), encoding p6250:  Firstly these genes, when mutated, can cause 
ALS.  Secondly, these genes all have a role in protein degradation via both the autophagy 
and ubiquitin proteasome systems.  Thirdly, the protein products of these genes are present 
in both the TDP-43-positive neuronal cytoplasmic inclusions as well as the TDP-43-negative 
neuronal cytoplasmic inclusions of C9ORF72-ALS.  Finally, the protein products are also 
present in ubiquitylated inclusions of neurodegenerative diseases other than ALS.  This 
stresses the role of protein catabolism in ALS specifically, and neurodegeneration more 
generally, when one considers the presence of such proteins in inclusions in conditions 
outside the ALS spectrum.  In support of this, it appears that optineurin facilitates protein 
aggregate51 and mitochondrial52 autophagy, the former function being disrupted by ALS-
causing OPTN mutations53.   
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Figure and table legends 
Table 1 OPTN nucleotide substitutions identified in Sheffield fALS and sALS cases.   
All mutations and polymorphisms listed have been reported according to the Human Genome Variation 
Society guidelines. Numbering is taken from the Ensembl transcript ID ENST00000378748 and 
NM_001008211. Genotype frequencies given are those for Europe provided by the 1000 Genomes Project 
Phase1. 
 
Table 2 In silico analysis summary of mutation effects. 
 
Figure 1 a Chromatograph readout showing the c.964G>A nucleotide substitution identified in the proband 
(II:5). b Pedigree diagram of the fALS family in which the mutation has been identified in exon 10 of the 
OPTN gene. Index case is indicated by an asterisk. WT = wild type, heterozygous for p.E322K. 
 
Figure 2 ClustalW2 multiple alignment of the optineurin protein sequence showing the highly conserved 
p.E322K amino acid in human (Homo sapiens: ENSP00000368022), chimpanzee (Pan troglodytes: 
ENSPTRP00000040385), mouse (Mus musculus: ENSMUSP00000110648), cow, (Bos taurus 
ENSBTAP00000021808), chicken (Gallus gallus: ENSGALP00000022287), zebrafish (Danio reno: 
ENSDARP00000099052) and African clawed frog (Xenopus laevis: ENSXETP00000019986). Location of 
the p.E322K mutation identified in the index case is boxed.    
 
Figure 3:  Neurohistology from the spinal cord of the proband reveals skein-like (arrow) and compact 
(arrowhead) ubiquitylated neuronal cytoplasmic inclusions in lower motor neurones evident on p62 (a, 
bar=100m) and TDP-43 (b, bar=100m) immunohistochemistry.  Degeneration of the pyramidal tract is 
revealed by myelin pallor of the lateral tracts on luxol fast blue staining in the spinal cord (c, bar=1mm) and 
the presence of ubiquitylated neuronal (arrow) and glial (arrowhead) cytoplasmic inclusions in the motor 
cortex (d, bar=50m).  Superimposed on this are TDP-43-negative neuronal cytoplasmic inclusions 
(arrows) in extra motor regions, e.g. the hippocampus (e, bar=50m) and the cerebellum (f, bar=50m). 
 
Figure 4:  Optineurin immunohistochemistry showing neuronal cytoplasmic staining in a neurologically 
healthy control (a, bar=100m), sporadic ALS patient (b, bar=100m) and the proband with OPTN and 
C9ORF72 mutations (c, bar=100m).  Optineurin intensely labels neuronal cytoplasmic inclusions (arrows) 
in sporadic ALS (b) and the proband (c).  Optineurin also labels a subset of TDP-43-negative extra motor 
inclusions (arrows) in the hippocampus (d, bar=50m) and cerebellum (e, bar=50m) as well as a case 
carrying a C9ORF72 but not an OPTN mutation (f, hippocampus, bar=50m).  Double labelling 
immunohistochemistry of the cerebellum in the index case shows colocalisation of optineurin and poly-GA 
dipeptide repeat (g). 
Supplementary figure 1:  Adjacent sections stained for optineurin or ubiquitin reveal neuronal cytoplasmic 
inclusions that are positive for both optineurin and ubiquitin in the same cells (black arrows) or cells that 
contain neither ubiquitylated nor optineurin-positive inclusions (white arrows; bar = 50m).   
